Digitalis glycosides: mechanisms and manifestations of toxicity. Part I.
D000818:Animals; D001682:Biological Availability; D003892:Deslanoside / Q000378:metabolism; D004071:Digitalis Glycosides / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism / Q000633:toxicity*; D004074:Digitoxin / Q000008:administration & dosage / Q000378:metabolism / Q000633:toxicity; D004077:Digoxin / Q000008:administration & dosage / Q000378:metabolism / Q000633:toxicity; D004347:Drug Interactions; D004573:Electrolytes / Q000378:metabolism; D004912:Erythrocytes / Q000378:metabolism; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects; D007700:Kinetics; D007799:Lanatosides / Q000378:metabolism; D009203:Myocardial Infarction / Q000188:drug therapy; D010042:Ouabain / Q000378:metabolism; D011485:Protein Binding / Q000187:drug effects; D012463:Saliva / Q000378:metabolism; D013327:Strophanthidin / Q000031:analogs & derivatives / Q000378:metabolism
D004071:Digitalis Glycosides; D004573:Electrolytes; D007799:Lanatosides; D010042:Ouabain; C018548:lanatoside C; D013327:Strophanthidin; D004077:Digoxin; D004074:Digitoxin; C004681:acetylstrophanthidin; D003892:Deslanoside